Pure Global AI
NCT06293664Recruiting

Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes

Randomized Cross-over Designed Study of the Physiological Impact of Alpha MSH on Glycemic Response to an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes
Dasman Diabetes InstituteClinicalTrials.govother
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
α-MSH infusion
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Dasman Diabetes Institute
Location
Kuwait City, Kuwait
Timeline & enrollment
Phase
N/A
Start date
Mar 04, 2024
End date
Apr 04, 2024
Enrollment
13 participants
Primary outcome

Difference in the total or incremental area under the curve of glucose and insulin concentration at an OGTT during saline vs. α-MSH infusion

Summary

Alpha-melanocyte stimulatory hormone (α-MSH) is a melanocyte-stimulating hormone produced by
 the hypothalamus and released from the pituitary gland. It acts as an agonist to the
 melanocortin 5 receptor (MC5R) in human skeletal muscle, playing a role in glucose uptake and
 disposal. This study aims to investigate whether α-MSH can enhance glucose tolerance in
 patients with Type 2 Diabetes Mellitus (T2DM).

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06293664
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06293664 through Pure Global AI's free database. This phase not specified trial is sponsored by Dasman Diabetes Institute and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 13 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.